Introduction
Malaria is a global public health threat, particularly in tropical and
sub-tropical countries [1]. The majority of malaria episodes
reported annually worldwide are from the Sub-Saharan African countries
including Sudan [1,2]. Unfortunately, Sudan suffers from several
infectious diseases with overlapping symptoms creating additional
challenges in the case definition and management [3–6]. This delay
in identifying the cases, reporting, and management is contributing to
the increase of malaria burden [7–9]. In Sudan, the national
malaria treatment guidelines recommend using Artesunate/Lumefantrine as
a first-line treatment for uncomplicated falciparum malaria, and
Artesunate or Quinine for treating the severe infections [10]. This
case report presents a severe subconjunctival hemorrhage due to severe
consecutive vomiting that was induced by the intake of
artemether/lumefantrine for malaria treatment.